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Circulating endothelial progenitor cells (EPCs) are a hierarchy of pluripotent cells in 
peripheral blood capable of differentiating into mature endothelial cells destined for blood 
vessel formation[1]. These cells have the ability to be mobilized to the site of vascular injury 
or tissue ischemia, and they differentiate into mature endothelial cells. They are a major 
determinant of a postnatal mechanism for neovascularization and vascular remodeling, and 
play an important role in endothelial cell and vessel maintenance. However, in patients with 
atherosclerosis and cardiovascular disease, EPCs are reduced in number and impaired in 
function, which are negatively correlated with the atherosclerotic risk factors, and may 
contribute to vascular dysfunction[2]. For example, the frequency of circulating EPCs is 
reduced 50% in patients with coronary artery disease, and their EPCs display an impaired 
migratory response[3]. Moreover, although EPCs successfully restore endothelial function 
and enhance angiogenesis after tissue ischemia in animal models, the clinical 
administration of EPCs to patients has had limited efficacy. It is likely that EPCs are 
targets of endogenous angiogenic inhibitors elaborated in the setting of atherosclerosis. 
Therefore, understanding the factors and mechanisms that affect EPC function and 
number may not only provide new insights into the pathogenesis of vasculogenesis, but 
also promote development of specific therapies to ultimately correct EPC dysfunction and 
prevent progression of atherosclerosis. 
The plasma kallikrein–kinin system (KKS) consists of the proteins factor XII, prekallikrein, 
and high molecular weight kininogen (HK)[4-5]. This system widely participates in 
maintenance of the cardiovascular phenotype, and displays multiple physiologic and 
pathophysiological activities, such as blood pressure adjustment, modulation of thrombosis, 
regulation of endothelial cell function and angiogenesis.  Plasma HK, which is synthesized 
and released from the liver, is a major component of the KKS and is responsible for the 
association of the KKS with cell surface. The plasma membrane of endothelial cells is an 
important site for the assembly and activation of the KKS. Activation of the KKS is triggered 
in vivo by tissue destruction or by thrombus development, and results in cleavage of HK by 
kallikrein and generation of two-chain HK (HKa) and a nonapeptide bradykinin[6]. HKa 
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and bradykinin differentially regulate the endothelial cell function, HKa is antiangiogenic, 
but bradykinin is of proangiogenesis. Unlike HK, HKa exposes its domain 5 to the surface 
on cleavage, thereby acquiring a function of antiadhesion. This antiadhesive property 
enables HKa to inhibit endothelial cell proliferation and to induce endothelial apoptosis on 
extracellular proteins, thus it exhibits potent antiangiogenic activity[7-8]. The inhibitory 
effect of HKa may result from its inhibition of ǂvǃ3 integrin function[7, 9], and induction of 
apoptosis via its interaction with uPAR[10]. Because EPCs express high levels of uPAR, 
which is a HKa receptor, HKa may exerts inhibitory effect on EPCs[11]. In this chapter, we 
summarize the recent observations that the KKS regulates EPC function.  
Human EPCs can be isolated from adult circulation. If EPCs are to be defined as true 
progenitor cells with postnatal vasculogenic potential, they should give rise to differentiated 
progeny with the capacity for vessel formation. In a 3D collage gel, EPCs, but not 
differentiated endothelial cells such as HAECs and HUVECs, exhibit strong capacity to form 
vacuoles and tubes in the presence of VEGF[11], suggesting that EPCs are unique in their 
stronger potential for tubular morphogenesis and are more sensitive to physiological 
growth factor stimulation.  
2. HKa inhibits EPC tube formation via suppression of MMP-2 activation 
In the process of neovascularization, invasive endothelial cells secrete MMPs to remodel the 
extracellular matrix (ECM) and the basal lamina – an important physical barrier between the 
endothelial and connective tissue[12]. Two members of the MMP family, MMP-2 and MMP-
9, display the highest enzymatic activities against the ECM components important in 
angiogenesis. MMP-2 and MMP-9 participate in the mobilization of EPCs. Recently we have 
demonstrated that MMP-2 is selectively required for VEGF-stimulated vasculogenic 
differentiation of EPCs[11]. In the conditioned culture media of EPCs embedded in 3D 
collagen gel, VEGF selectively stimulated the secretion and activation of MMP-2, but not 
MMP-9, and VEGF-stimulated proMMP-2 expression and secretion are time-dependent, the 
secreted proMMP-2 was meanwhile converted into active form. As the specific inhibitor of 
MMP-2 (444244), but not MMP-9 (444278), concentration-dependently attenuated VEGF-
stimulated tube formation by EPCs, suggesting the role of MMP-2 activities in tube 
formation by EPCs[11].   The requirement of MMP-2 and MMP-9 expression for the tube 
formation by EPCs is examined by specific siRNA oligonucleotides. VEGF-stimulated tube 
formation by EPCs was almost completely suppressed by gene silencing of MMP-2, but not 
of MMP-9. [11] Thus, MMP-2 is selectively required for EPC formation of tubular structures. 
The inhibitory effect of the MMP-2 gene silencing was more potent than that of the 
enzymatic inhibitor, suggesting that both the catalytic activity and expression of MMP-2 are 
necessary for the tubular morphogenesis of EPCs. Indeed, pro-MMP-2 possesses enzymatic 
activity-independent functions; its interaction with cell-surface proteins may mediate 
intracellular activation signals. Collectively, as found by using pharmaceutical inhibitors 
and gene ablation, both the enzymatic activity and expression of MMP-2 are required for 
EPC differentiation. This observation is consistent with a recent study showing that MMP-2 
deficiency reduces the functional activities of EPCs, leading to impaired vasculogenesis[12].  
Interestingly, HKa markedly inhibits conversion of pro-MMP-2 to active MMP-2 in EPCs 
without affecting MMP-2 secretion. In a 3D culture system, HKa significantly decreased 
VEGF-stimulated tube formation by EPCs at the concentrations of 30 nmol /L, 100 nmol/ L 
and 300 nmol/ L, representing cleavage of HK of 4.5%, 15% and 45%, respectively, which 
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occurs in experimental inflammatory bowel disease and arthritis[11]. VEGF-stimulated 
MMP-2 secretion and activation was not detected in the medium of EPCs cultured on 
collagen-coated surfaces, suggesting that MMP-2 is not involved in EPC activation in a 2D 
system and HKa did not inhibit endothelial cell function on collagen surfaces[11]. Thus, 
HKa inhibition of tube formation by EPCs in collagen gel (3D system) reveals a novel 
mechanism for HKa antiangiogenic activities. In a 3D system MMP-2 activation is very 
likely a target for HKa. The MMP-2 Inhibitor I (444244) markedly abolished the gelatinolytic 
activity of both proform and active form of MMP-2. In contrast, HKa treatment only 
reduced the ratio of active MMP-2 to total MMP-2 (44 ± 7% at 0 nmol/ L vs. 27 ± 6% and 
19 ± 3% at 100 and 300 nmol/L, respectively)[11]. Thus, HKa inhibits the conversion of pro-
MMP-2 to active MMP-2. In purified systems, HKa at 300 nmol/ L did not have apparent 
inhibition of catalytic activity of MMP-2 and the conversion of pro-MMP-2 to MMP-2[11]. 
Collectively, HKa inhibits the conversion of pro-MMP-2 to MMP-2 in EPCs without directly 
affecting MMP-2 secretion and activity. Because the KKS activation may occur during 
inflammation and thrombosis, HKa as an activation product of this system may induce EPC 
dysfunction in the setting of pathological conditions.  
3. HKa inhibition of MMP-2 activation in EPCs is dependent on αvβ3 integrin 
EPCs expressed a high level of ǂvǃ3 integrin and HKa downregulates ǂvǃ3 integrin ligand 
binding affinity in endothelial cells, whether HKa inhibition of MMP-2 activation through 
ǂvǃ3 integrin was examined by an ǂvǃ3CS-1 cell line[11]. In the ǂvǃ3-CS-1 cells, the 
expression of ǂvǃ3 integrin on the cell surface increased MMP-2 activation and stimulated 
autoactivation of MMP-2 (conversion of 64-kDa to 62-kDa form)[11]. However, in the 
presence of HKa, the conversion of proMMP-2 to 64- and 62-kDa forms was inhibited. 
Correspondingly, HKa blocked the formation of avǃ3 integrin-MMP2 complex in EPCs 
cultured in a 3D gel[11]. HKa disrupts the association between ǂvǃ3 integrin and proMMP-
2, which may account for its inhibition of MMP-2 activation[11]. MMP-2-ǂvǃ3 integrin 
interaction is critical for angiogenesis, HKa inhibition of MMP-2 activation and tube 
formation by EPCs is, at least in part, mediated through ǂvǃ3 integrin. Therefore, HKa 
inhibits the vasculogenic differentiation by EPCs via the suppression of MMP-2 activation, 
which is a novel activity of the KKS system. The inhibitory effect of HKa on MMP-2 is 
dependent on the presence of ǂvǃ3 integrin and mediated by the dissociation of proMMP-2 
from ǂvǃ3 integrin. The ǂvǃ3 integrin is necessary for vascular cell survival, proliferation 
and invasion during angiogenesis. MMP-2 activation has been suggested to be downstream 
of ǂvǃ3 integrin activation, and MMP2- ǂvǃ3 binding is required for proper MMP2 
function. This is consistent with MMP-2 and ǂvǃ3 integrin being colocalized in a particular 
membrane fraction caveolae, which enhances cellular protrusive activity. The disruption of 
MMP-2 binding to ǂvǃ3 integrin blocks angiogenesis in vitro and in vivo; ǂvǃ3 integrin may 
serve as an MMP-2 receptor in the process of angiogenesis. In endothelial cells, the primary 
target for HKa is uPAR and HKa occupancy of uPAR disrupts uPAR-ǂvǃ3 integrin complex 
formation. HKa seems to indirectly modulate ǂvǃ3 integrin function. In platelets, ǂIIbǃ3 
integrin also interacts with the C-terminal hemopexin-like domain of MMP-2, suggesting 
that MMP-2 is likely to be associated with ǃ3 subunit[13]. In a purified system, ǂvǃ3 
integrin did not form a complex with pro-MMP2 or active MMP-2, supporting the 
observation that MMP-2, which does not have a RGD sequence, indirectly interacts with 
ǂvǃ3 integrin via a mediatory RGD-bearing molecule. Alternatively, MMP-2 may bind to 
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ǂvǃ3 integrin in a RGD-independent manner, as cRGDfK failed to completely prevent the 
association between proMMP-2 and ǂvǃ3 integrin. Strikingly, HKa possesses stronger 
inhibition of both pathways. Taken together, HKa, by interfering with ǂvǃ3 integrin 
function, decreases the ligation of proMMP2 or its associated molecule to ǂvǃ3 integrin in 
EPCs, thereby suppressing MMP-2 activation. The inhibitory effect of HKa on MMP-2, at 
least in part, accounts for its inhibition of EPC vasculogenic differentiation.  
HKa inhibition of the tube forming capacity of EPCs reveals a novel activity of the 
components of the KKS in vascular dysfunction and expands our understanding of the 
pathophysiological activities of this system. Local EPCs recruited after early arterial injury 
incorporate into foci of postnatal vasculogenesis and exhibit strong potential for vascular 
repair. A study using kininogen-deficient mice indicates that the KKS activation, in the 
process of vascular injury, induces arterial thrombosis[6]. Thus, developing thrombus in 
atherosclerotic lesions may form a surface that promotes the assembly of the components of 
the KKS, leading to a secondary activation of this system and further production of HKa. 
HKa inhibition of vasculogenesis of EPCs proposes a novel concept that activation of the 
KKS may contribute to EPC dysfunction. Although it remains to be determined whether and 
how HKa inhibition of EPCs is involved in the disordered vascular remodeling in vivo, 
recognition of components of plasma KKS modulation of EPC function allows for the 
beginning of understanding its pathophysiologic activities in atherosclerosis. 
4. HKa suppresses clonogenic capacity of EPCs 
Clonogenic capacity of EPCs can be analyzed using a single-cell assay. [14]. To test whether 
HKa affects the clonal expansion potential of EPCs, a single-cell suspension of EGFP-EPCs 
was seeded into 96-well culture plate precoated with collagen, in order to test whether HKa 
affects the clonal expansion potential of EPCs. The culture medium EGM-2 was replaced 
every 2 days. After culture for 14 days, EGFP-EPCs formed large colonies, and ≈85% of 
colonies contained more than 200 cells (large colonies). However, in the presence of 50 
nmol/L HKa, the percentage of large colonies was markedly reduced to <6% (P<0.001), 
indicating that HKa strongly inhibits clonogenic capacity of EPCs[14]. 
5. HKa inhibits EPC proliferation without induction of apoptosis 
HKa inhibition of EPC colony formation suggested that HKa suppresses proliferation of 
EPCs. The effect of HKa on proliferative capacity of EPCs was examined using a 5-bromo-2′-
deoxyuridine (BrdU) incorporation assay. Treatment of EPCs with HKa for 72 hours 
significantly inhibited vascular endothelial growth factor–stimulated BrdU incorporation 
into EPCs, and the inhibition was concentration-dependent, whereas the significant 
inhibitory effect of HKa was detectable only at 100 nmol/L after treatment for 48 hours. In 
contrast to its significant effects on proliferation, HKa at the same concentrations did not 
inhibit EPC adhesion to collagen[14], suggesting that HKa inhibition of EPC proliferation 
does not result from an antiadhesion activity. Because HKa induces apoptosis of 
differentiated endothelial cells on vitronectin-coated surfaces, the effect of HKa on EPC 
apoptosis was examined. HKa did not induce EPC apoptosis on collagen surfaces, although 
its effect on induction of EPCs apoptosis on vitronectin-coated plates was significant. 
Therefore, HKa inhibition of EPC colony formation and proliferation is not subject to 
antiadhesive activity and induction of apoptosis.  
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6. HKa accelerates the onset of EPC senescence and suppresses telomerase 
activity 
Reduction of EPCs in number and activity is associated with EPC senescence. The common 
features of senescent endothelial cells include the enhanced presence of acidic ǃ-
galactosidase activity, an increase in lysosomal mass, and formation of autophagic vacuoles. 
To determine whether HKa induces EPC senescence, the activity of acidic ǃ-galactosidase 
was measured, the former referred as senescence-associated-ǃ-galactosidase (SA-ǃ-gal). 
Although a small portion of EPCs were positive for SA-ǃ-gal staining after culture for 14 
days, in the presence of 50 nmol/L HKa the majority of EPCs became positive for SA-ǃ-gal 
staining[14]. Moreover, EPCs treated with 50 nmol/L HKa displayed a unique flattened and 
enlarged morphology and formed intracellular vacuoles[14], HKa treatment significantly 
resulted in an increase in SA-ǃ-gal-positive cells, 17.2±2.6% vs 52.3±3.7% on day 7 and 
22.3±2.7% vs 85.5±7.9% on day 14[14]. Acceleration of the onset of EPC senescence is known 
to be critically influenced by the level of telomerase activity, which elongates telomeres, 
thereby counteracting telomere length reduction induced by each cell division. Therefore, 
whether HKa treatment was capable of regulating telomerase activity in EPCs was tested. 
Treatment of EPCs with 50 nmol/L HKa for 14 days markedly diminished telomerase 
activity by >60% (P<0.005)[14], serving as additional evidence for HKa acceleration of EPC 
senescence.  
7. HKa increases intracellular ROS production, contributing to EPC 
senescence 
Cell senescence is tightly associated with intracellular ROS production. Whether HKa 
exposure increases intracellular ROS in EPCs was tested using the 2′-7′-
dichlorodihydrofluorescein diacetate (H2DCF-DA) labeling assay. In a concentration-
dependent manner, HKa significantly increased H2DCF-DA oxidation level in exposed 
EPCs[14]. Further whether HKa accelerates EPC senescence via ROS production was tested 
in an inhibition assay using the ROS scavengers Mn(III)tetrakis(4-benzoic acid)porphyrin 
chloride (MnTBAP) and N-acetylcysteine (NAC). MnTBAP is a cell-permeable superoxide 
dismutase mimetic and peroxynitrite scavenger. NAC is an efficient free radical scavenger 
and contributes to production of other antioxidant species. Treatment with either 100 
μmol/L NAC or 10 μmol/L MnTBAP significantly attenuated the increase in ROS 
production in EPCs treated with 100 nmol/L HKa for 12 hours[14]. Moreover, 100 μmol/L 
NAC or 10 μmol/L MnTBAP significantly reduced both the percentage of senescent cells 
and ROS production in EPCs treated with 50 nmol/L HKa for 14 days[14]. These 
observations suggest that HKa generation of ROS is involved in the acceleration of EPC 
senescence.  
8. HKa upregulates p38 kinase phosphorylation and p16
INK4a
 expression  
To investigate the mechanism for HKa acceleration of EPC senescence, we measured the 
levels of p38 kinase activation and prosenescence molecule p16INK4a expression, which are 
downstream of ROS generation in the process of cellular senescence. Immunoblotting 
analysis indicated that treatment with HKa at 30 and 100 nmol/L for 7 days increased p38 
kinase phosphorylation[14]. Concomitantly, HKa upregulated p16INK4a expression at the 
protein and mRNA levels. Since 10 μmol/L SB203580, a specific p38 kinase inhibitor, 
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markedly suppressed HKa-induced p16INK4a expression as well as EPC senescence, HKa 
upregulates p16INK4a expression via its activation of p38 kinase[14].  
The above observation demonstrates novel activities of HKa in regulating several key 
elements of EPC biology. Aging is associated with an increased risk for atherosclerosis, and 
insufficient repair of damaged vascular walls by a diminished number or dysfunction in 
EPC is one of many possible causes. A reduction in EPC number and activity has been 
associated with EPC senescence. Because senescence limits the ability of EPCs to sustain 
ischemic tissue repair, a full characterization of the pathophysiological factors leading to 
EPC senescence, as well as the related underlying mechanisms, is clearly important. Our 
current study demonstrating HKa acceleration of EPC senescence not only expands our 
understanding of the KKS activation in the regulation of vascular biology but also reveals a 
potential novel endogenous inducer of EPC senescence.  
The in vivo activation of the KKS and cleavage of HKa has been widely detected in 
numerous pathophysiological conditions, such as thrombosis, arthritis, inflammatory bowel 
disease, vasculitis, sepsis, systemic amyloidosis, and preeclampsia[4]. However, how the 
KKS activation products initiate and regulate downstream effects remains elusive. The 
plasma concentration of HK is 660 nmol/L. In patients with sepsis and autoimmune 
diseases, more than 30% of plasma HK was cleaved[15]. Because the minimal concentration 
of HKa that significantly induced EPC senescence was 30 nmol/L, the circulating levels of 
HKa in the pathological settings could affect EPC function. This HKa-mediated effect was 
associated with profoundly impaired EPC clonal expansion potential and resulted in a low 
overall proliferative capacity of the EPC progeny. Because HK is localized at sites of 
vascular injury, such as atherosclerotic lesions, it might become cleaved over the abundant 
negative-charged surfaces to release HKa. The observation that HKa potently inhibited the 
clonogenic capacity of EPCs suggests that HKa is possibly involved in the vascular 
dysfunction by blocking EPC aggregation and expansion. Because HKa inhibition of EPC 
function is not dependent on its antiadhesion activity, HKa in plasma may attack circulating 
EPCs. Whether the blockade of HK cleavage prevents EPC senescence remains to be 
determined using an in vivo model.  
EPC senescence can be triggered by a variety of factors, such as proinflammatory cytokines, 
DNA damage, hyperoxia, and hyperglycemia.  All these factors increase oxidative stress, by 
which they induce EPC senescence and suppress telomerase activity. The mechanism by 
which HKa accelerates the onset of senescence of EPCs seems to be tightly associated with 
ROS production. NAC and MnTBAP, which quench ROS, significantly attenuated HKa-
induced EPC senescence. A previous study has shown that HKa inhibits Akt 
phosphorylation and endothelial nitric oxide synthase phosphorylation, which may inhibit 
the production of nitric oxide (NO). Although NO prevents endothelial cell senescence, the 
NO donor S-nitrosopenicillamine did not prevent HKa-accelerated onset of EPCs 
senescence. Thus, HKa regulation of EPC senescence appears independent of the NO 
pathway. Accumulation of ROS in most cell types is associated with high expression of 
p16INK4a, which leads to the arrest of the cell cycle at the G1 phase and accelerates senescence 
of cells.The expression of p16INK4a increases with age and contributes to age-dependent stem 
and progenitor cell senescence. It can be deduced that accumulative ROS exposure, caused 
by various atherosclerotic risk factors, may also increase the expression of p16INK4a in EPCs, 
contributing to EPC senescence. We found that HKa increased expression of p16INK4a at the 
mRNA and protein level, demonstrating that HKa accelerates EPC senescence by the 
regulation of p16INK4a expression. We previously have found that p38 kinase is responsible 
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for mediating the effect of HKa in other cells. Our observations in this study indicate that 
HKa enhances phosphorylation of p38 kinase, and the inhibition of p38 kinase prevented 
both HKa-induced p16INK4a expression and EPC senescence. Therefore, HKa-induced ROS 
seems to act through p38 kinase to upregulate prosenescence molecule p16INK4a expression, 
which may further regulate telomerase activity and result in EPC senescence.  
9. Bradykinin upregulates CXCR4 mRNA expression and stimulates 
transendothelial migration (TEM) of EPCs 
TEM is an essential step for the EPC homing to sites of inflammatory and ischemic tissues. 
In a TEM assay using 96-transwell filters, EPCs were cultured on collagen-coated transwell 
filters until becoming confluent, CFDA-SE-labeled EPCs in endothelial basal medium (EBM-
2) containing 2% FBS were placed on top of the lung microvessel endothelial cells (LMEC) 
monolayer. EBM-2 containing 2% FBS and bradykinin was added to the lower 
compartment. After incubation at 37°C for 18 hrs, the filters were fixed with 2% PFA. EPCs 
migrating into the lower side of the filters were visualized with a fluorescent microscope 
and counted in 6 random microscopic fields. Bradykinin (a B2R agonist) dose-dependently 
increased the transmigration of EPCs. In contrast, des-Arg9-BK (a B1R agonist) did not have 
such effect (data not shown). B2R predominantly mediates transmigration of normal EPCs. 
Treatment with bradykinin dose-dependently increased CXCR-4 mRNA expression in EPCs, 
but not the expression of other homing receptors such as E-selectin and 4-integrin.   
In conclusion, HKa inhibits vasculogenic differentiation of EPCs and accelerates the onset of 
their senescence, and bradykinin upregulates transendothelial migration capacity. These 
activities of HKa and bradykinin reveal a novel link between KKS activation and EPC 
function, and it expands our understanding of the additional pathophysiological activities of 
this system. Although it remains to be determined whether and how HKa and bradykinin 
regulate the function of EPCs in the disordered vascular remodeling that occurs in vivo, our 
novel recognition that components of plasma KKS modulate EPC function allows for 
focused determination of the pathophysiologic activities of plasma KKS in atherosclerosis in 
future studies, provides an improved understanding of the contribution of the KKS cascade 
to EPC dysfunction in vitro and suggest candidate pathways for investigation of EPC 
dysfunction in subjects with vascular pathology.  
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